REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/11/2025
Back to search
Official data from USPTO
ALTAVANT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALTAVANT
ST13
US500000079251701Class
5, 42, 44
Filing
79251701
Registration
5980178
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
02/11/2025
Trademark type
Word
Nice classes
5, 42, 44
Filing date
12/14/2018
Registration date
02/11/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/11/2020
Last transaction
02/11/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
HISER, CHARLES
Law office
O30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Altavant Sciences GmbH
Representatives
Allison Strickland Ricketts Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for the treatment of pulmonary arterial hypertensionpulmonary fibrosissarcoidosisrespiratory diseasesdisorders and conditions; biologic preparations for medical and therapeutic purposes for the treatment of pulmonary arterial hypertensionpulmonary fibrosissarcoidosisrespiratory diseasesdisorders and conditions
Class 42
Scientific and technological servicesmedical researchscientific research and analysis in the field of pharmaceuticals and biomedicine; pharmaceuticalbiomedical and biological therapeutic research services; scientific research in the fields of pharmaceutical and biologic therapeutic preparationsclinical trials and post-market trials; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticalsbiomedicineclinical trials and post-market trials
Class 44
Providing health and medical information; providing information relating to the diagnosticprophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseasesdisorders and conditions
Publications
History of USPTO decisions and trademark events.
24 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/19/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/02/2020
FIMP
FINAL DISPOSITION PROCESSED
06/02/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/11/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
02/11/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/26/2019
PUBO
PUBLISHED FOR OPPOSITION
11/26/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/06/2019
ALIE
ASSIGNED TO LIE
10/21/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/15/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/07/2019
RFNP
REFUSAL PROCESSED BY IB
04/26/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/18/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/08/2019
RFRR
REFUSAL PROCESSED BY MPU
04/08/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/19/2019
CNRT
NON-FINAL ACTION WRITTEN
03/18/2019
DOCK
ASSIGNED TO EXAMINER
03/12/2019
MAFR
APPLICATION FILING RECEIPT MAILED
02/23/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/19/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/14/2019
Continuous trademark protection
Get notified about every new filing that threatens ALTAVANT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.